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1117-85 Influence of Body Mass Index on Acute Coronary 
Syndrome Outcomes: Lessons From the Global 
Registry of Acute Coronary Events
Kamala Tamirisa, Dietrich C. Gulba, Catherine Kim, Martin Klutmann, Christoph 
Tillmans, Kami White, Kim A. Eagle, The GRACE Investigators, University of Michigan 
Medical School, Ann Arbor, MI, Krankenhaus Düren, Düren, Germany
Background The relationship between body mass index (BMI) and acute coronary syn-
drome (ACS) outcomes is controversial. The aim of this study was to investigate the risk
profile and outcomes of ACS patients according to BMI category.
Methods We examined data from 19,318 patients enrolled in the GRACE registry.
Patients were stratified into BMI categories (kg/m2): <20, 20-25, >25-30, >30. Assessed
outcomes included hospital mortality, bleeding and stroke rates. Logistic regression was
used to adjust analyses for baseline characteristics and ACS type.
Results Of the 19,318 ACS patients, when compared to reference patients (BMI 20-25),
those with BMI >30 had more diabetes mellitus, hypertension, hyperlipidemia and diag-
nostic coronary angiograms, whereas BMI <20 had more heart failure and smoking his-
tory. Older patients had lower BMI compared to younger patients. On further
stratification, death rates were higher in >70 years of age in all BMI groups and either
gender, except in males with BMI <20, where the mortality was similar in both age
groups. We found no association between BMI and hospital mortality in men with ACS.
Women with BMI <20 had a trend toward higher hospital mortality compared to reference
(Table 1) and received less CABG.
Conclusions Women (particularly those >70 years) with ACS and BMI <20 showed a
trend for increased hospital mortality after adjustment for clinical characteristics. There
was no association between BMI and ACS outcomes in men.
1117-86 Do Differing C-Reactive Protein Assay Methods Impact 
Cardiovascular Risk Assessment?
Jessica L. Clarke, Jeffrey L. Anderson, John F. Carlquist, Richard F. Roberts, Benjamin 
D. Horne, Tami L. Bair, Matthew J. Kolek, Chrissa P. Mower, Ashle M. Crane, Ted J. 
Hollist, William L. Roberts, Joseph B. Muhlestein, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City, UT
Background: Serum C-reactive protein (CRP) is acknowledged as an independent risk
marker for primary and secondary prevention of coronary artery disease (CAD). Several
assays are available and have been used; however, little information is available about
their comparability, especially in diseased populations.
Methods: Two assays were compared in a cohort of 805 consenting patients who had
blood drawn during angiography for suspected or known CAD and were followed for 2.6 ±
1.3 y. Frozen samples from the patients were tested by a particle-enhanced immunoturbi-
dimetric assay (Tina-quant, Roche, R) and by a fluorescence polarization immunoassay
(Abbott, A). CRP analysis was performed non-parametrically or after logarithmic (ln)
transformation or division into quartiles (Q). Spearman’s test was used for correlations
and logistic regression for predictive modeling.
Results: The study population had an average age of 62 years; 73% were male; 26%,
smokers; 78% had angiographic CAD; 62%, hypertension; 69%, hyperlipidemia; 25%,
diabetes; and 16%, prior MI. During follow-up, 168 events occurred. Median CRP differed
substantially by assay overall (A=13.4, R=3.21 mg/L) and in those without (N=176) and
with (N=627) CAD. However, correlations of lnCRP-A vs. lnCRP-R were high (r=0.824,
p<<0.001); 4Q CRP assays were congruent in 88% of pt and within 1 Q in 98% by both
assays. Overall, 65% of tests were congruent and 96% within 1 Q. Both assays indepen-
dently predicted death/nonfatal MI (D/MI), with 4Q vs. 1Q odds ratio (OR) for CRP-
A=1.78 (1.11-2.84) and for hsCRP-R=1.90 (1.17-3.10) in stepwise modeling including 7
standard risk factors. CRQ-A also independently predicted angiographic CAD (p=0.007),
4Q/1Q OR=1.67.
Conclusion: Although the absolute CRP values differed substantially between the two
assays in our large study were substantial (4-fold difference in median values), they were
highly correlation by Q rank and equally predictive of D/MI. These results emphasize the
robust within-assay predictive value of CRP and should assist in comparing values deter-
mined from various assays across different studies and in standardizing assay methods
for the future.
1117-87 Does the Presence of Q Waves in the Infarct-Leads at 
the Presentation of an ST Elevation Myocardial 
Infarction Predict 30-Day Outcome After Fibrinolytic 
Therapy? Results From the HERO-2 Trial
Cheuk-Kit Wong, Harvey D. White, The HERO-2 Investigators, Green Lane Hospital, 
Auckland, New Zealand, Dunedin Medical School, Dunedin, New Zealand
Background: The evolution of pathological Q waves in the infarct leads during a ST ele-
vation acute myocardial infarction reflects ongoing myocardial necrosis.
Aim: We determined if the presence of pathological Q waves in the infarct leads at pre-
sentation would predict 30-day mortality after fibrinolytic therapy.
Methods and results: In 15,222 patients with ST elevation during normal intraventricular
conduction randomised in the Hirulog Early Reperfusion Occlusion (HERO) –2 trial,
10,244 patients (67.3%) had and 4,978 (32.7%) did not have initial Q waves. All patients
received aspirin, streptokinase and either unfractionated heparin or bivalirudin. The 30-
day mortality was higher in patients with than in patients without initial Q waves (10.2%
vs 6.9%, P<0.0001). In the 12,456 patients who also satisfied the criteria for analysing
ST resolution at 60-minute, patients with initial Q waves had less frequent ST resolution
than patients without initial Q waves (51.7% vs 56.9% for >30% ST resolution, P<0.0001;
and 12.9% vs 18.9% for >70% ST resolution, P<0.0001). These differences in mortality
and ST resolution were seen in all subgroups stratified by time to randomization or by inf-
arct-location, and in patients who had a first infarction.
On multivariable analysis including usual clinical prognostic predictors, the presence of
initial Q waves independently predicted 30-day mortality (P<0.0001). In a second model
including also ST measurements in the 12,456 patients, Q waves in the infarct leads
remained significant in predicting higher 30-day mortality (adjusted odds ratio 1.31, 95%
confidence interval 1.12-1.54; P<0.0001). There was an early separation of the survival
curves of patients with and patients without initial Q waves. Other electrocardiographic
predictors were baseline ST elevation, baseline ST depression and resolution of ST ele-
vation at 60 minutes. There was no interaction between initial Q waves and 60-minute ST
resolution in predicting 30-day mortality (P=0.619).
Conclusion: Q wave in the infarct lead group at the presentation of a ST elevation acute
myocardial infarction independently predicted a higher 30-day mortality.
1117-88 High-Density Lipoprotein, but Not Low-Density 
Lipoprotein Cholesterol Levels Influence Short-Term 
Prognosis After Acute Coronary Syndrome: Results 
From the MIRACL Trial
Anders G. Olsson, Gregory G. Schwartz, Michael D. Ezekowitz, Peter Ganz, Michael F. 
Oliver, David Waters, Andreas Zeiher, William Sasiela, Michael Szarek, The MIRACL 
Trial Investigators, University of Linkoping, Linkoping, Sweden, VA Medical Center and 
University of Colorado Health Sciences Center, Denver, CO
The MIRACL trial demonstrated that intensive treatment with atorvastatin, initiated
shortly after acute coronary syndrome (ACS), reduces early recurrent ischemic events.
The present prespecified analysis determined the influence of serum lipoprotein concen-
trations and treatment on short-term outcomes after ACS. Methods: Cox proportional
hazards models determined relations among lipoproteins, treatment (atorvastatin 80 mg
daily or placebo), and time to a primary endpoint event (death, nonfatal AMI, cardiac
arrest, or urgent rehospitalization for recurrent myocardial ischemia) during the 16-week
trial. One analysis related lipoproteins measured at baseline (prior to treatment) to events
from randomization to Week 16. Another analysis related the change in lipoproteins from
baseline to Week 6 (on treatment) to events occurring during Weeks 6-16. Hazard ratio
(95% CI) for a recurrent ischemic event was expressed per mg/dl increase in a lipopro-
tein measurement. Results: There was no independent influence of baseline total cho-
lesterol, triglycerides, or LDL-C on 16 week risk of an ischemic event, with a hazard ratio
of 1.000 (0.997-1.003) for LDL-C. In contrast, higher baseline HDL-C was independently
associated with reduced risk [0.986 (0.979-0.994, p<.001]. Stated another way, each mg/
dl increment in baseline HDL-C reduced risk of an event by 1.4%. In multivariate analy-
sis, assignment to treatment with atorvastatin, compared to placebo, was associated with
reduced risk of an ischemic event, with hazard ratio 0.835 (0.699-0.999). Although atorv-
astatin reduced LDL-C by 55% compared to placebo at 6 weeks, the change in LDL-C on
randomized treatment had no effect on the risk of an event [1.001 (0.995-1.004)]. Atorv-
astatin had no significant effect on HDL-C at 6 weeks. Conclusions: Short-term progno-
sis after ACS is not influenced by baseline levels of LDL-C, but is favorably influenced by
higher baseline levels of HDL-C. The reduction in early recurrent ischemic events after
ACS with atorvastatin cannot be explained by the concurrent reduction in LDL-C, sug-
gesting that mechanisms unrelated to circulating lipoproteins (pleiotropic effects) may be
responsible for the clinical benefit.
1117-89 The Acuteness Score: New Insights in Predicting Infarct 
Size
Jacobus S. de Villiers, Yuling Fu, Galen Wagner, Shaun G. Goodman, Christopher B. 
Granger, Lars Wallentin, Frans Van de Werf, Paul W. Armstrong, for the ASSENT 3 
Investigators, University of Alberta, Edmonton, AB, Canada
Background: Early fibrinolytic therapy reduces mortality in acute ST elevation myocar-
dial infarction (MI). Since symptom onset time is subjective we adapted a previously
developed Acuteness Score (AS) that uses phasing of ST, T and Q waves to provide a
potentially more objective measurement of the evolutionary status of an MI (earliest 4.0
to latest 1.0). We used the ASSENT-3 ECG data to validate the usefulness of the AS by
evaluating its relationship to ST resolution (STR) 60 minutes after fibrinolysis and to inf-
arct size as assessed by discharge QRS score.
Methods: A total of 4272 pts from the ASSENT 3 study were stratified into 2 groups
based upon a previously established cut point of high (AS >3), 2727(63.8%) or low acute-
ness (AS <3), 1545(36.2%).
Table 1: BMI and In-hospital Death in Women
BMI (kg/m2) Crude Mortality Adjusted Mortality Adjusted OR (CI)
<20 10.8% 7.4% 1.5 (0.96, 2.28)
20-25 6.7% 5.3% Reference
>25 5.0% 5.1% 0.96 (0.73, 1.26)
